<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527500</url>
  </required_header>
  <id_info>
    <org_study_id>CLFG316A2203</org_study_id>
    <nct_id>NCT01527500</nct_id>
  </id_info>
  <brief_title>Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The amendment is designed to test the safety and efficacy of lower and higher doses of
      Intravitreal (IVT) LFG316 using single and 18 successive monthly injections in patients with
      geographic atrophy (GA). The study will also provide information on the safety, tolerability,
      serum concentrations and pharmacodynamics of single and multiple IVT doses of LFG316.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth of GA lesions as measured by fundus autofluorescence (FAF) from baseline to month 12</measure>
    <time_frame>Day 1 to Day 337 (starting from the day of first intravitreal injection until the end of the study)</time_frame>
    <description>FAF is a non-invasive imaging procedure that measure the size of the GA lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events from single and multiple doses of IVT LFG316 in GA patients</measure>
    <time_frame>Day 1 to Day 589</time_frame>
    <description>safety and tolerability of LFG316 from BL through D589</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events from 12 successive, every 4 weeks, IVT doses of LFG316 in GA patients</measure>
    <time_frame>Day 1 to Day 337 (starting from the day of first intravitreal injection until the end of the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in best corrected visual acuity (BCVA) as measured on the ETDRS (Early Treatment in Diabetic Retinopathy Study) scale from 12 successive, every 4 weeks, IVT doses of LFG316</measure>
    <time_frame>Day 1 to Day 337 (starting from the day of first intravitreal injection until the end of the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total LFG316 and total C5 in the blood during the course of the study from single dose and 12 successive, every 4 weeks, IVT doses of LFG316 (lower and higher dose)</measure>
    <time_frame>Day 1 to Day 337 (starting from the day of first intravitreal injection until the end of the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of 6 and 18 successive, every 4 weeks, IVT doses of LFG316 on GA lesion</measure>
    <time_frame>D1, D169 and D477</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>LFG316 higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFG316 higher dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316 lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFG316 lower dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <description>LFG316 20 mg/0.2 mL solution (in 2 mL vial) for IVT injection,</description>
    <arm_group_label>LFG316 higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFG316 Lower dose</intervention_name>
    <description>LFG316 20 mg/0.2 mL solution for IVT Injection</description>
    <arm_group_label>LFG316 lower dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AMD

          -  Geographic atrophy in at least one eye

          -  ETDRS best corrected visual acuity of 60 letters or worse (~â‰¤ 20/63)

        Exclusion Criteria:

          -  Retinal disease other than AMD

          -  History of choroidal neovascularization

          -  Severe cataract

          -  History of infectious uveitis or endophthalmitis

          -  Eye surgery in the non-study eye within 30 days prior to study

          -  Eye surgery or IVT injection in the study eye within 90 days prior to study

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85704-5614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105-3153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912-7125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beachwood/Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Age-related Macular Degeneration</keyword>
  <keyword>geographic atrophy</keyword>
  <keyword>GA</keyword>
  <keyword>Dry AMD</keyword>
  <keyword>Blindness</keyword>
  <keyword>Drusen</keyword>
  <keyword>GA lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 24, 2016</submitted>
    <returned>August 11, 2016</returned>
    <submitted>December 19, 2016</submitted>
    <returned>February 10, 2017</returned>
    <submitted>March 17, 2017</submitted>
    <returned>April 27, 2017</returned>
    <submitted>May 3, 2017</submitted>
    <returned>June 5, 2017</returned>
    <submitted>August 3, 2017</submitted>
    <returned>September 1, 2017</returned>
    <submitted>October 24, 2017</submitted>
    <returned>November 30, 2017</returned>
    <submitted>December 14, 2017</submitted>
    <returned>January 12, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

